Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07619482 · ClinicalTrials.gov registry record · Phase 1
Topical Insulin for Glaucoma (TING2)
A Phase 1 study, sponsored by Stanford University.
- Not yet
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
NCT07619482: Clinical Trial Phase 1 study, sponsored by Stanford University.
NCT07619482 is a Phase 1 study that has not yet begun recruiting, run by Stanford University. The registered enrollment target is 90 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07619482, a Phase 1 study, has not yet begun recruiting, sponsored by Stanford University.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
Study Summary
This study evaluates the safety and preliminary efficacy of topical sterile human insulin eye drops (EYED-002) in patients with open-angle glaucoma. The study uses a phase 1/2 dose-escalation design followed by a masked, randomized, placebo-controlled phase. Insulin is formulated as preservative-free eye drops and delivered once daily. The primary objective is to determine the safety profile of topical insulin; secondary objectives assess effects on retinal structure, visual field, visual acuity, contrast sensitivity, and quality of life.
Interventions
- DRUG EYED-002 Low Dose (721 U/mL topical insulin)
- DRUG EYED-002 High Dose (1442 U/mL topical insulin)
- DRUG EYED-002 (highest tolerated dose, 12-month)
- DRUG Vehicle Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-06 |
| Est. Completion | 2029-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07619482
The ClinicalTrials.gov registry entry for NCT07619482 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which EYED-002 Low Dose (721 U/mL topical insulin) is the first listed.
NCT07619482 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07619482 about?
NCT07619482 is a clinical study titled "Topical Insulin for Glaucoma (TING2)". This study evaluates the safety and preliminary efficacy of topical sterile human insulin eye drops (EYED-002) in patients with open-angle glaucoma. The study uses a phase 1/2 dose-escalation design followed by a masked, randomized, placebo-controlled phase. Insulin is formulated as preservative-fre...
What is the current status of trial NCT07619482?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2026-06. Estimated completion is 2029-10.
What interventions are being tested in trial NCT07619482?
The interventions under investigation include: EYED-002 Low Dose (721 U/mL topical insulin) (DRUG), EYED-002 High Dose (1442 U/mL topical insulin) (DRUG), EYED-002 (highest tolerated dose, 12-month) (DRUG), Vehicle Placebo (DRUG).
Who is sponsoring clinical trial NCT07619482?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.